Eric Johansen

Title: Eric Johansen: Innovator in Antigen-Binding Molecules

Introduction

Eric Johansen is a notable inventor based in Oakland, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antigen-binding molecules. With a total of 3 patents, his work focuses on innovative methods for targeting specific antigens related to cancer treatment.

Latest Patents

Johansen's latest patents include groundbreaking compositions targeting prostate-specific membrane antigen (PSMA). This patent describes antigen-binding molecules that exhibit binding specificity to CD T cell receptors and PSMA. It also details the use of cleavable linker sequences and protease-activatable bispecific fusion proteins, which have potential applications in cancer therapies. Another significant patent involves HER-2 targeted bispecific compositions. This invention outlines polypeptides and methods for creating bispecific antibody constructs that can be cleaved by proteases, allowing for targeted therapeutic applications.

Career Highlights

Throughout his career, Eric Johansen has worked with prominent companies in the biotechnology sector. He has been associated with Amunix Pharmaceuticals, Inc. and Dh Technologies Development Pte. Ltd. His work in these organizations has contributed to advancements in therapeutic technologies and drug development.

Collaborations

Johansen has collaborated with notable professionals in his field, including Volker Schellenberger and Darragh Maccann. These collaborations have fostered innovation and the sharing of ideas, further enhancing the impact of his work.

Conclusion

Eric Johansen is a distinguished inventor whose contributions to antigen-binding molecules are paving the way for new cancer treatments. His innovative patents and collaborations highlight his commitment to advancing biotechnology.